<DOC>
	<DOCNO>NCT01012765</DOCNO>
	<brief_summary>This study conduct assess effect indacaterol ( 150 μg o.d . ) inspiratory capacity ( IC ) , use placebo open label tiotropium ( 18 μg o.d . ) comparators patient moderate chronic obstructive pulmonary disease ( COPD ) . In particular , spirometric timepoints include elucidate peak-IC period approximately 4 hour post inhalation</brief_summary>
	<brief_title>Effect Indacaterol Inspiratory Capacity ( IC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Cooperative outpatient diagnosis COPD ( moderate classify GOLD Guidelines , 2008 ) include : Smoking history least 10 pack year Postbronchodilator FEV1 &lt; 80 % ≥50 % predict normal value ( Visit 2 ) . Postbronchodilator FEV1/forced vital capacity ( FVC ) &lt; 70 % ( Visit 2 ) . Patients receive corticosteroid ( include inhale ) 3 month prior screen Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>indacaterol</keyword>
	<keyword>QAB149</keyword>
	<keyword>inspiratory capacity</keyword>
</DOC>